An IL-5 Single-Nucleotide Polymorphism Influences Neuroinflammation and Prospective Disease Activity in Multiple...

Area of Science:

• Neuroimmunology
• Genetics of Autoimmune Diseases
• Cytokine Signaling in Multiple Sclerosis

Background:

• Multiple sclerosis (MS) involves complex central nervous system inflammation and neurodegeneration.
• Genetic factors contribute to individual variability in MS clinical presentation.
• The IL-5 rs2069812 polymorphism's role in MS pathogenesis is unexplored.

Purpose of the Study:

• To investigate the association between the IL-5 rs2069812 polymorphism and central neuroinflammation in MS.
• To determine the influence of this polymorphism on the clinical course of MS.
• To analyze cerebrospinal fluid (CSF) inflammatory mediator levels in relation to the polymorphism and MS subtypes.

Main Methods:

• Genotyping of the IL-5 rs2069812 single-nucleotide polymorphism (SNP) in 230 MS patients (RR-MS and P-MS) and controls.
• Measurement of CSF levels of various pro-inflammatory and anti-inflammatory cytokines.
• Correlation analysis between the rs2069812 genotype, cytokine levels, and clinical outcomes, including No Evidence of Disease Activity (NEDA-3).

Main Results:

• MS patients exhibited higher pro-inflammatory cytokines (IL-2, IL-6, IL-12, GM-CSF) and lower anti-inflammatory cytokines (IL-5, IL-1ra) in CSF compared to controls.
• The T-allele of rs2069812 was associated with increased pro-inflammatory mediators in MS patients, while the CC genotype correlated with higher anti-inflammatory mediators.
• In relapsing-remitting MS (RR-MS) patients, the CC genotype was significantly associated with achieving No Evidence of Disease Activity (NEDA-3) at three years.

Conclusions:

• The IL-5 rs2069812 polymorphism plays a role in modulating central neuroinflammation in MS.
• This genetic variation influences the clinical course, with the CC genotype potentially indicating a less active disease state in RR-MS.
• The study highlights a novel genetic marker for predicting MS disease activity and response to treatment.